Double-blind randomized comparison of intravenous @entity11797 versus @entity3303 in the treatment of chronic XXXX .

@entity1 @entity1165 @entity11797 @entity3303 @entity1540 @entity943
The efficacy and safety of intravenous @entity11797 were compared with intravenous @entity3303 in @entity1 with chronic @entity943 in a double-blind, parallel study. Twenty-nine @entity1 were randomized to a @entity11797 (n = 15) or @entity3303 (n = 14) group. Antiarrhythmic efficacy was defined as a greater than or equal to 50% reduction in single @entity1540 ( @entity1540 ) frequency, greater than or equal to 90% reduction in paired @entity1540 frequency, and total abolition of @entity1165 . Efficacy was observed in 40% (6 of 15) of @entity1 in the @entity11797 group and in 36% (5 of 14) @entity1 in the @entity3303 group. A 75% or greater reduction in total VPCs occurred in 40% (6 of 15) of @entity1 in the @entity11797 group and in 57% (8 of 14) of @entity1 in the @entity3303 group. Greater than 90% suppression of paired VPCs occurred in 9 of 13 (69%) @entity1 taking @entity11797 and in 6 of 11 (54%) @entity1 taking @entity3303 . Total abolition of @entity1165 was documented in 5 of 11 (45%) @entity1 given @entity11797 and in two of six (33%) @entity1 given @entity3303 . A total of 17 adverse reactions affecting 86% (12 of 14) of @entity1 taking @entity3303 and 11 adverse reactions affecting 53% (8 of 15) of @entity1 taking @entity11797 occurred. Four @entity1 in each treatment group suffered dose-limiting adverse effects. This study suggests that the efficacy and safety of intravenous @entity11797 are similar to that of intravenous @entity3303 in @entity1 with chronic @entity943 .
